Medivir

Medivir Net Debt

The Net Debt of Medivir (MVIR.ST) as of Oct 28, 2026 is -53.52 M SEK. In the previous year, Net Debt was -90.63 M SEK — a change of -40.95% (higher).

Net Debt

-53.52 MSEK

YoY

-40.95%

Last updated:

Net Debt of Medivir is 2020 -53.52 M SEK. Net Debt of Medivir was 2019 -90.63 M SEK. It decreases by -40.95% higher compared to the previous year.

The Medivir Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2014
-1.36 B SEK
Jan 1, 2016
-1.70 B SEK
Jan 1, 2017
-467.78 M SEK
Jan 1, 2018
-286.28 M SEK
Jan 1, 2019
-90.63 M SEK
Jan 1, 2020
-53.52 M SEK
The Medivir Net Debt history
YEARNet DebtYoY
-53.52 MSEK-40.95%
-90.63 MSEK-68.34%
-286.28 MSEK-38.80%
-467.78 MSEK-72.46%
-1.70 BSEK+25.29%
-1.36 BSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medivir Stock analysis

What does Medivir do? Medivir AB generates revenue by developing pharmaceutical products, specifically focusing on protease inhibitor design and nucleoside and nucleotide science to create therapies for cancers with unmet medical need. The company operates from its headquarters in Huddinge, Stockholm, and relies on a specialized team of nine full-time employees to drive its research and development efforts. The firm's financial model is supported by its clinical pipeline, which includes remetinostat, a topical histone deacetylase inhibitor currently in phase II clinical studies for cutaneous T-cell lymphoma. Additionally, the company is advancing birinapant in combination with Keytruda for solid tumors in phase I studies, MIV-818 for liver cancer in phase I trials, and MIV-711 for osteoarthritis in an IIa extension study. Beyond these specific assets, Medivir AB sustains its operations through additional research projects conducted in cooperation with other institutions. This collaborative approach complements its internal development programs and contributes to the overall value of its proprietary science and therapeutic candidates. Medivir is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medivir stock

Net Debt of Medivir is -53.52 M SEK in 2020.

Net Debt of Medivir changed from -90.63 M SEK to -53.52 M SEK, representing a -40.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Medivir since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Medivir historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Medivir

All Key Metrics — Medivir